Yahoo won't let me put the link on here. You can find it fairly easy. Main page,featured abstracts, Advaxis
Boom. I think the results thru Feb 2013 look great. Final figures at meeting
Don't worry from the new S-1 they plan on a re-do
During the next 12 months, our strategic goals and objectives include the following:
• Complete our Phase 2 clinical study in India of ADXS-HPV in the treatment of recurrent/refractory cervical cancer, optimize the dose and schedule through additional Phase 1/2 trials and finalize the registration strategy;
If the results are posted, and the results are great, then why wouldn't there already be a press release this morning from Diana Moore. I would think this press release would have been prepared a week ago and ready to be sent out to multiple news sources at 5:00 this morning. Hmmmm.
Busted - I haven't seen you weigh in on the proxy discussions (maybe I missed it). You've been here a long time and hold an influential number of shares - if you don't mind my asking, do you support any of the proposals?
So at this point, we have a 54.5% improvement over the absolute best SOC results seen to date (22% survival rate).
Results: As of February 2013, the trial has completed enrollment and 110 patients have received 264 doses of ADXS11-001. The percentage of patients alive at 6 months is 63% (67/107); at 9 months is 46% (49/106); at 12 months is 34% (30/87) and at 18 months is 15% (8/54). Tumor responses have been observed in both treatment arms with 6 CRs and 6 PRs; 36 additional patients had stable disease 3 months, for a disease control rate of 44% (48/110). Activity against different high risk HPV strains has been observed. Three serious adverse events and 69 mild-moderate adverse events possibly related/related to ADXS11-001 treatment have been reported in 41% (45/110) of patients. The non-serious adverse events consisted predominately of transient, non-cumulative flu-like symptoms associated with infusion that either resolved on their own or responded to symptomatic treatment. Conclusions: ADXS11-001 can be safely administered to patients with advanced cancer alone and in combination with chemotherapy. ADXS11-001 is well tolerated and presents a predictable and manageable safety profile. Final 12-month OS, updated safety and translational analyses will be presented at the meeting.
Chemo alone has a median survival rate of 13.3 months, so what is the average survival rate in these 110 patients as of today not knowing how long the remaining 15% of patients could live to. In other words if SOC is 13.3 months is advaxis survival rate at least 17 months?
I think we also have to remember that these results have come in a country that's medical facilities are not as good as in the US. Disease is much more prevalent in and outside hospitals, and the conditions that some of these patients live in, is far below US standards. And ADXS results are still above anything else seen in any other phase 2. I expect GOG results to be much better.